Lippo China Res-NEW (00156) has announced an expected consolidated loss attributable to shareholders of approximately HK$60 million for the fiscal year ending December 31, 2025. This compares to a consolidated loss of HK$684 million recorded in the previous fiscal year ended December 31, 2024.

The projected improvement in the loss position is primarily attributed to several factors. These include a net fair value gain of about HK$4 million on financial instruments at fair value through profit or loss for the 2025 fiscal year, a reversal from the net fair value loss of HK$63 million recorded in the 2024 fiscal year. Additionally, a tax provision of approximately HK$104 million was reversed during the current year.

Other contributing factors to the reduced loss include a HK$386 million litigation settlement amount recognized in 2024, a decrease in other operating expenses, and the net change in fair value of the group's financial instruments classified at fair value through profit or loss, alongside the aforementioned tax provision reversal.